Core Viewpoint - NeuroOne Medical Technologies Corporation is advancing epilepsy treatment through its innovative OneRF Ablation System, which combines brain activity monitoring and radiofrequency ablation in a single device, aiming to improve patient outcomes and reduce the need for multiple surgeries [1][4][3]. Company Overview - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) focuses on developing minimally invasive and high-definition solutions for neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The company is exploring applications for its technology in various areas such as depression, mood disorders, and high blood pressure [5]. Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing seizures that do not respond to medication, highlighting the need for alternative treatment options like RF ablation therapy [2]. - The OneRF Ablation System is the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously, representing a significant advancement in the treatment of epilepsy [3].
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace